State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors

XLV has outperformed IXJ, returning 21.81% over one year and growing a hypothetical $1,000 investment to $1,346 over five years, versus IXJ's 16.04% and $1,243. XLV also charges a materially lower 0.08% expense ratio versus 0.38% for IXJ and manages $43.2 billion versus $4.3 billion. IXJ offers wider global diversification with 110 holdings, compared with XLV's 60 U.S. healthcare stocks, while XLV carries higher concentration in its top holdings.

Analysis

This is not a standalone healthcare-beta signal: both vehicles are dominated by the same U.S. megacap pharmaceutical complex, so the apparent domestic-versus-global choice is primarily a concentration, currency, and non-U.S. valuation trade. The meaningful incremental exposure in IXJ is to European and Japanese pharma/medtech, where slower growth is partly offset by generally lower multiples, weaker currencies, and potentially less direct exposure to U.S. drug-pricing reform. XLV is therefore the cleaner expression of sustained U.S. GLP-1, oncology, and large-cap biotech leadership, but it also carries materially greater single-name sensitivity to LLY.

The fee differential is economically relevant for strategic allocations but too small to drive a near-term relative-value trade; a 30 bp annual drag only becomes decisive over multi-year holding periods. Near term, XLV/IXJ relative performance will be determined by whether LLY and other U.S. innovators can continue delivering upward earnings revisions faster than European defensives, not by headline diversification. The key risk is that LLY’s weight converts an idiosyncratic obesity-market disappointment, supply normalization, or pricing pressure into sector-level ETF underperformance.

Contrarianly, global exposure becomes attractive if the next healthcare leg is mean reversion rather than innovation-led momentum. A U.S. dollar decline, rotation away from crowded GLP-1 beneficiaries, or renewed M&A among European large pharma would favor IXJ despite its structural fee handicap. Watch relative EPS revisions for LLY/ABBV/JNJ versus NOVN/ROG/SNY and the USD index over the next 1-3 months; without a reversal there is no compelling reason to pay up for IXJ.

Key Decisions for Investors

• For a 6-18 month core healthcare allocation, prefer XLV over IXJ: lower carrying cost and greater capture of U.S. large-cap earnings momentum. Do not add aggressively after broad healthcare rallies; scale on a 5-8% sector pullback or when forward EPS revisions stabilize.
• Use a tactical long XLV / short IXJ pair only if U.S. healthcare earnings revisions remain superior and LLY holds above its 200-day moving average; target 5-8% relative return over 3-6 months. Exit if LLY guidance is cut, U.S. drug-pricing policy advances materially, or USD weakens more than 5% from entry.
• For managers concerned that XLV is an unintended LLY concentration trade, own XLV alongside a partial LLY hedge rather than substituting IXJ wholesale. The hedge is most relevant into LLY earnings, obesity-trial data, manufacturing-capacity updates, and reimbursement decisions.
• Set a rotation alert for improving European pharma revisions and a sustained USD downtrend. If both occur, shift incremental healthcare exposure toward IXJ for 6-12 months; the likely payoff would come from multiple mean reversion and FX translation, not from the ETF's broader holding count.